{"entity":{"id":"nct05251714","kind":"trial","name":"CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer","aka":[],"tldr":"A phase 1/2 trial of Fulvestrant in advanced solid tumours, run by Treadwell Therapeutics, Inc, active and no longer recruiting.","summary":"CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer is a phase 1/2 interventional study registered as NCT05251714 by Treadwell Therapeutics, Inc, with 44 participants enrolled, started 2022-05-27 and due to reach its primary completion in 2026-08. Interventions recorded: CFI-402257 and Fulvestrant.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05251714","url":"https://clinicaltrials.gov/study/NCT05251714"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["fulvestrant"],"companies":["treadwell-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05251714","phase":"1/2","setting":"A Dose-confirming Study of CFI-402257 as a Single Agent in Advanced Solid Tumors and in Combination With Fulvestrant in Patients With ER+/HER2- Advanced Breast Cancer After Disease Progression on Prior CDK4/6 and Endocrine Therapy","sponsor":"Treadwell Therapeutics, Inc","enrolled":44,"outcomes":[]},"route":"/trials/nct05251714/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/"}],"company":[{"id":"treadwell-therapeutics","kind":"company","name":"Treadwell Therapeutics","route":"/companies/treadwell-therapeutics/"}]}}